Different types of antineuronal antibodies have been uncovered in patients with epileptic seizures and autoimmune encephalitis over the past decade, including those directed against the N-methyl-D-aspartate receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), and gamma-aminobutyric acid receptor (GABAR) (4), and their pathogenicity of these antineuronal surface-antigen antibodies has been documented (5–7). This evidence concerns the gene LGI1 and autoimmune encephalitis.